{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-209874","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.906285+00:00","generated_at":"2026-06-11T15:35:57.042091+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IO Biotech Q2 net loss $21.2M; Phase 3 melanoma trial reaches 225-patient milestone; $75M private placement closed","bullets":["Net loss of $21.2M (vs $18.5M Q2 2022); R&D spend $16.5M on Phase 3 trial execution.","Cash and equivalents $110.1M; expected to fund operations into Q4 2025.","Phase 3 IOB-013/KN-D18 enrolled 225 patients; target raised to 380, full enrollment by end 2023.","Interim ORR analysis one year post 225 randomized may support US accelerated BLA submission.","Appointed Heidi Hunter to Board; Priyanka Belawat resigned; closed $75M private placement (37M shares+warrants)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-209874","json":"https://secwatch.observer/filing/0001193125-23-209874.json","markdown":"https://secwatch.observer/filing/0001193125-23-209874.md","text":"https://secwatch.observer/filing/0001193125-23-209874.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523209874/0001193125-23-209874-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523209874/d524431d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T15:35:57.042091+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66e499ce0f68ba0d998e2ee161aa8da32aa422a3","claim":"IO Biotech, Inc. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was $21.2 million.","evidence_excerpt":"Net loss for the three months ended June 30, 2023 was $21.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523209874/0001193125-23-209874-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the three months ended June 30, 2023 was $21.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"023e2383d9","claim":"Priyanka Belawat resigned as Director at IO Biotech, Inc..","evidence_excerpt":"On August 7, 2023, Priyanka Belawat, a member of the Board of Directors of the Company, notified the Company of her resignation from the Board, effective that same date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523209874/0001193125-23-209874-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b7e852a009","claim":"Heidi Hunter was appointed as Class II director at IO Biotech, Inc..","evidence_excerpt":"On August 8, 2023, the Company appointed Heidi Hunter as a Class II director of the Company, effective as of August 11, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523209874/0001193125-23-209874-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}